{
  "id": 3985610,
  "title": "AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease",
  "url": "https://urgent.news/2026/08/28/astrazeneca-ionis-data-spark-debate-about-rna-drugs-impact-on-deadly",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-28T14:58:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/astrazeneca-ionis-eplontersen-nejm-cardio-ttransform-results/829057/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs",
        "url": "https://urgent.news/2026/08/28/stat-in-autopsy-of-failed-heart-disease-study-astrazeneca-raises",
        "published": "2026-08-28T09:23:13.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}